Company Encyclopedia
View More
name
bioAffinity Tech
BIAF.US
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
1.935 T
BIAF.USMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking171/401
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-245.18%E
    • Profit Margin-217.50%E
    • Gross Margin34.84%C
  • Growth ScoreD
    • Revenue YoY-27.66%E
    • Net Profit YoY-74.51%E
    • Total Assets YoY76.23%A
    • Net Assets YoY185.23%A
  • Cash ScoreD
    • Cash Flow Margin-45.98%D
    • OCF YoY-27.66%E
  • Operating ScoreB
    • Turnover0.75B
  • Debt ScoreA
    • Gearing Ratio22.90%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    bioAffinity Tech | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.446 M

    LB filings·
    US
    BIAF
    -4.88%
    LB filings·
    US
    BIAF
    -4.88%

    bioAffinity Tech | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 1.446 M

    LB filings·
    US
    BIAF
    -4.88%
    LB filings·
    US
    BIAF
    -4.88%

    Pre-market hot trades in US stocks: bioAffinity Tech pre-market down 10.16%; Apogee Therapeutic pre-market down 9.61%

    bioAffinity Tech pre-market down 10.16%; Apogee Therapeutic pre-market down 9.61%; Global Health Solutions pre-market up 207.14%; Alaunos Therapeutics pre-market up 111.62%; Baosheng Group pre-market up 76.74%

    Tracking Unusual Activity·
    US
    BIAF
    -4.88%
    US
    APGE
    -0.99%
    Tracking Unusual Activity·
    US
    BIAF
    -4.88%
    US
    APGE
    -0.99%

    Pre-market hot trades in US stocks: Eightco up 8.92% in pre-market; bioAffinity Tech down 7.55% in pre-market

    Eightco pre-market up 8.92%; bioAffinity Tech pre-market down 7.55%; Ango Alliance pre-market up 217.04%; Zooz Power pre-market up 118.45%; Chijet Motor pre-market up 77.79%

    Tracking Unusual Activity·
    US
    ORBS
    -10.96%
    US
    BIAF
    -4.88%
    Tracking Unusual Activity·
    US
    ORBS
    -10.96%
    US
    BIAF
    -4.88%

    bioAffinity Tech | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 1.269 M

    LB filings·
    US
    BIAF
    -4.88%
    LB filings·
    US
    BIAF
    -4.88%
    © 2025 Longbridge｜Disclaimer